Evogene Files Investor Presentation, CEO Haviv to Present

Ticker: EVGN · Form: 6-K · Filed: Jan 9, 2024 · CIK: 1574565

Complexity: simple

Sentiment: neutral

Topics: investor-presentation, corporate-update, management-insight

TL;DR

**Evogene just dropped an investor presentation, get ready for management's latest pitch.**

AI Summary

Evogene Ltd. filed a 6-K on January 9, 2024, to include an investor presentation dated January 10, 2024. This presentation, led by President & CEO Ofer Haviv, likely outlines the company's strategic direction, financial performance, and future prospects. For investors, this matters because it provides updated information directly from management, which could influence their perception of the stock's value and future growth potential.

Why It Matters

This filing provides investors with the latest company presentation, offering insights into Evogene's strategy and outlook directly from its leadership, which can impact investment decisions.

Risk Assessment

Risk Level: low — This filing is purely informational, providing an investor presentation, and does not inherently introduce new financial or operational risks.

Analyst Insight

An investor should review the attached investor presentation (Exhibit 99.1) to understand Evogene's current strategy and future outlook, as presented by CEO Ofer Haviv, before making any investment decisions.

Key Players & Entities

Forward-Looking Statements

FAQ

What is the purpose of this 6-K filing by Evogene Ltd.?

The purpose of this 6-K filing is to furnish an investor presentation, Exhibit 99.1, which is incorporated by reference into the report.

Who signed this 6-K filing on behalf of Evogene Ltd. and what is their role?

The 6-K filing was signed by Yaron Eldad, who holds the position of Chief Financial Officer for Evogene Ltd.

When was the investor presentation, Exhibit 99.1, dated?

The investor presentation, Exhibit 99.1, is dated January 10, 2024.

Who is identified as the presenter of the investor presentation?

The investor presentation is identified as being presented by Ofer Haviv, who is the President & CEO of Evogene Ltd.

What is Evogene Ltd.'s Commission File Number?

Evogene Ltd.'s Commission File Number is 001-36187.

Filing Stats: 197 words · 1 min read · ~1 pages · Grade level 11.5 · Accepted 2024-01-09 08:30:57

Filing Documents

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot, Rehovot P.O.B 4173, Ness Ziona, 7414002, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____ CONTENTS Attached hereto and incorporated by reference herein is the following exhibit: 99.1 Evogene Investor Presentation. Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: January 9, 2024 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing